2024-03-29T13:53:22Z
https://niigata-u.repo.nii.ac.jp/oai
oai:niigata-u.repo.nii.ac.jp:00016300
2022-12-15T03:47:47Z
453:456
471:537:538:1102
6)腎細胞癌に対するサイトカイン治療(シンポジウム サイトカインの基礎と臨床応用, 第537回新潟医学会)
6)腎細胞癌に対するサイトカイン治療(シンポジウム サイトカインの基礎と臨床応用, 第537回新潟医学会)
Cytokine Therapy of Renal Cell Cancer
斎藤, 俊弘
片桐, 明善
冨田, 善彦
renal cell cancer
cytokine therapy
interferon
interleukin-2
腎細胞癌
サイトカイン治療
インターフェロン
インターロイキン2
Metastatic renal cell cancer (RCC) is usually treated with immunotherapy using cytokines because it is a mostly chemoresistant malignancy. These therapies are generally based on interleukin-2 (IL-2) or interferon. However, their response rates were less than 20% and various side effects appeared. In order to improve response rate or reduce side effects, we have tried LAK (lymphokine-activated killer cells) therapy and low dose interferon γ therapy. LAK cells are peripheral blood lymphocytes activated in vitro by exposure to IL-2. LAK therapy was done 10 course for 9 patients in our hospital and the overall respones rate was 60%. On the other hand, low dose interferon γ therapy was done for 10 patients and the side effects were relatively small with the response rate of 10%. These results indicate that immunotherapy using cytokines are useful for metastatic renal cancer and its strategy, including dosage, combination therapy, is still to be investigated.
新潟医学会
1998-11
jpn
departmental bulletin paper
http://hdl.handle.net/10191/46337
https://niigata-u.repo.nii.ac.jp/records/16300
AN00182415
00290440
新潟医学会雑誌
新潟医学会雑誌
112
11
690
692
https://niigata-u.repo.nii.ac.jp/record/16300/files/112(11)_690-692.pdf
application/pdf
523.4 kB
2019-08-07